Viz.ai, and NICO Corporation—a leader in modern minimally invasive interventional technologies for neurosurgery—have announced a collaboration to incorporate a new innovative clinical trial recruitment software from Viz.ai into the seminal ENRICH study which is investigating the treatment of intracerebral hemorrhages.

Viz.ai, Inc., a leading applied artificial intelligence company in healthcare, and NICO Corporation, a leader in modern minimally invasive interventional technologies for neurosurgery, have announced a collaboration to incorporate a new innovative clinical trial recruitment software from Viz.ai into the seminal ENRICH study which is investigating the treatment of intracerebral hemorrhages (ICHs).

Viz.ai, Inc., an applied artificial intelligence company, has been designated as a compatible vendor for the American Heart Association/American Stroke Association Get With The Guidelines registry, the premier program for assisting hospitals in measuring and improving cardiovascular disease and stroke care through research-based guidelines.

In stroke care, time is brain. The winner of the Best New Radiology Software award -- Viz LVO from software developer Viz.ai -- is designed to speed up diagnosis and treatment by serving as an early-warning system. The software analyzes CT angiography (CTA) images after acquisition and immediately notifies providers that a patient may be having a stroke.

Artificial intelligence (AI) health care startup Viz.ai has raised $21 million in a round of funding led by Kleiner Perkins, with participation from Alphabet’s venture capital arm GV. Founded out of San Francisco in 2016, Viz.ai is setting out to leverage AI to detect early signs of time-sensitive medical conditions. The company’s first product is a software platform that analyzes brain scans for large vessel occlusions (LVOs), or strokes, and which received FDA clearance in February.

The potential benefits are great. As Tom Devlin, a stroke neurologist at Erlanger, observes, “We know we lose 2m brain cells every minute the clot is there.” Yet the two therapies that can transform outcomes—clot-busting drugs and an operation called a thrombectomy—are rarely used because, by the time a stroke is diagnosed and a surgical team assembled, too much of a patient’s brain has died. Viz.ai’s technology should improve outcomes by identifying urgent cases, alerting on-call specialists and sending them the scans directly.

The technology from Viz.ai (the ai is for artificial intelligence) recently gained Food and Drug Administration approval. The company and Erlanger are talking to other Chattanooga hospitals about installing its diagnostic software there, which would allow neurologists to see brain scans almost simultaneously.

A Viz.ai study of 300 patients, which prompted the FDA approval, showed that the company’s software was able to notify a stroke neurologist on average 7.3 minutes after the brain imaging took place—compared with the hours that it sometimes takes with conventional diagnostic procedures. The technology accurately identified severe strokes as precisely as expert stroke radiologists do, the study found.

The system holds promise for improved outcomes, medical experts say, but only if it can be widely adopted by hospitals. One concern is cost. Companies developing the technology haven’t set a price but say it won’t be cost-prohibitive.

הם פועלים בתחומי הסייבר, האינטרנט של הדברים והמסחר האלקטרוני, וגם בבריאות ובחקלאות - וכולם רוצים לשנות את העולם עם רעיון חדשני והרבה התלהבות. מגזין אלה הסטארטאפים הישראליים שייעצבו את העתיד. לאיזה מהם הפוטנציאל הגדול ביותר? סמנו את הבחירה שלכם

Viz.ai, Inc., an applied artificial intelligence company, has further advanced the field of stroke imaging and workflow. Viz.ai has developed a novel method for the detection of signs of Large Vessel Occlusion Stroke (LVO) stroke in Non Contrast CT Head Scans (NCCT). Researchers from Emory University who independently assessed the new technology, will present a research study comparing the algorithm’s read of a NCCT with CT angiogram-based ground truth at the Society of Vascular and Interventional Neurology (SVIN) 2018 Annual Meeting.

Erlanger Health System, a multi-hospital health system based in Tennessee have announced a partnership with Viz.ai., a leading applied artificial intelligence company, to transform stroke care. The Erlanger Stroke Center is one of the foremost stroke centers in the nation.

Viz.ai, an applied artificial intelligence (AI) healthcare company focused on time sensitive conditions, has secured $21 million in Series A funding led by Kleiner Perkins, with participation from GV, formerly Google Ventures. Founded in 2016 by Dr. Chris Mansi and Dr. David Golan, Viz.ai has built the first FDA cleared computer aided triage software to detect and triage urgent stroke cases. The AI cloud-based platform analyzes brain scans for large vessel occlusions (LVOs) and sends the scan to a neurovascular specialist to facilitate early therapeutic intervention.

Viz.ai, Inc., an applied artificial intelligence healthcare company, announced today that new data on its approved and investigational technologies for acute ischemic and hemorrhagic stroke will be presented during the 4th European Stroke Organization Conference (ESOC) from May 16-18 in Gothenburg, Sweden.

Viz.ai, Inc., an applied artificial intelligence healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has cleared Viz CTP through the 510(k) pathway. Viz CTP offers image processing software to view and analyze functional and dynamic CT perfusion images. This clearance offers healthcare providers another important tool for automated cerebral-image analysis.

Viz.ai has ensured that its business structure and processes conform to ISO standards and, following audit, has received the following ISO Certifications: ISO/IEC 27001:2013, ISO 27017:2015, ISO 27018:2014, ISO 27799:2016 and ISO 22301:2012.

Viz.ai Inc. solutions and deployments based on Amazon Web Services (AWS) were reviewed (audited) by AWS, and found to match the highest requirements for security, reliability, performance efficiency, operational excellence and cost optimization set by the AWS Well-Architected Framework. The cover letter of the audit report, provided to Viz.ai by AWS reads:

... The Well-Architected review has been insightful on our part, and we hope you will find it useful as well. I’ve personally found your workload impressive and outstanding, both from the technological point of view, and because of the high standards ...

... Overall, your system is impressive and Well-Architected in many aspects. As a matter of fact, you are Well-Architected right now already ...

Viz.ai, Inc., an applied artificial intelligence healthcare company announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the first-ever Computer-Aided Triage and Notification Platform to identify Large Vessel Occlusion (LVO) strokes in CTA imaging. This regulatory clearance compliments Viz.ai's recent European CE Mark for the product in January 2018.